Company intelligence / Profile preview

Pearl Therapeutics

Redwood City, California, United Statesastrazeneca.com ↗

Ownership: Private
Employees: ~133
Development stage: Phase 3

Overview

Developed PT003 (fixed-dose combination bronchodilator with LAMA and LABA) and PT010 (triple-combination with LAMA, LABA, and ICS) for respiratory diseases. Successfully demonstrated combination superiority relative to individual components.

Therapeutic areas: Pulmonology
Modalities: Inhaled combination therapiesmetered dose inhaler (HFA MDI)
Industry: Biotech

Drug pipeline

2 assets

PT003

Phase 3

Indications: Chronic obstructive pulmonary disease

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pearl Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl Therapeutics.

Explore the full profile